.

Make Better Decisions

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Drug patents in 130+ countries

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

AstraZeneca
Argus Health
Daiichi Sankyo
McKesson
Federal Trade Commission
Cipla
Boehringer Ingelheim
Novartis
Medtronic
McKinsey

Generated: September 24, 2017

DrugPatentWatch Database Preview

PHOSLO Drug Profile

« Back to Dashboard

Which patents cover Phoslo, and what generic Phoslo alternatives are available?

Phoslo is a drug marketed by Fresenius Medcl and is included in two NDAs. There are two patents protecting this drug and one Paragraph IV challenge.

The generic ingredient in PHOSLO is calcium acetate. There are two hundred and sixty-eight drug master file entries for this compound. Thirty-four suppliers are listed for this compound. Additional details are available on the calcium acetate profile page.

Summary for Tradename: PHOSLO

Patents:1
Applicants:1
NDAs:2
Suppliers / Packagers: see list6
Bulk Api Vendors: see list29
Clinical Trials: see list6
Patent Applications: see list23
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:PHOSLO at DailyMed

Pharmacology for Tradename: PHOSLO

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Fresenius Medcl
PHOSLO
calcium acetate
CAPSULE;ORAL021160-001Apr 2, 2001DISCNNoNo► Subscribe► Subscribe► Subscribe
Fresenius Medcl
PHOSLO GELCAPS
calcium acetate
CAPSULE;ORAL021160-003Apr 2, 2001ABRXYesYes► Subscribe► SubscribeY ► Subscribe
Fresenius Medcl
PHOSLO
calcium acetate
CAPSULE;ORAL021160-002Apr 2, 2001DISCNNoNo► Subscribe► Subscribe ► Subscribe
Fresenius Medcl
PHOSLO
calcium acetate
TABLET;ORAL019976-001Dec 10, 1990DISCNYesNo► Subscribe► Subscribe► Subscribe
Fresenius Medcl
PHOSLO GELCAPS
calcium acetate
CAPSULE;ORAL021160-003Apr 2, 2001ABRXYesYes► Subscribe► Subscribe ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: PHOSLO

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Fresenius Medcl
PHOSLO
calcium acetate
CAPSULE;ORAL021160-001Apr 2, 2001► Subscribe► Subscribe
Fresenius Medcl
PHOSLO
calcium acetate
TABLET;ORAL019976-001Dec 10, 1990► Subscribe► Subscribe
Fresenius Medcl
PHOSLO
calcium acetate
CAPSULE;ORAL021160-002Apr 2, 2001► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV (Patent) Challenges for PHOSLO

Drugname Dosage Strength RLD Submissiondate
calcium acetateCapsulesEQ 169 mg calciumPhosLo5/31/2005

Non-Orange Book Patents for Tradename: PHOSLO

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,875,445 Encapsulated calcium acetate caplet and a method for inhibiting gastrointestinal phosphorous absorption► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

QuintilesIMS
US Army
Johnson and Johnson
Queensland Health
McKesson
Chubb
Chinese Patent Office
Fish and Richardson
Moodys
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot